ctDNA-guided adjuvant therapy in stage II-III melanoma
Most stage II patients never relapse, yet all are offered a year of immunotherapy. Use a blood test to treat only those with detectable residual disease.
KEYNOTE-716 and CheckMate 76K treat everyone in stage IIB/IIC for a modest absolute benefit. Tumour-informed ctDNA assays could identify the minority at risk. The DETECTION trial (UK) tests this approach.
Pages like this
not linked directly; found by shared links- IdeaA dedicated clinic for people whose blood test says the cancer is back
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaStarve the survivors: target the energy pathway drug-tolerant cells switch to
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Melanoma.
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaA national platform trial that every ctDNA-positive patient can join
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- Key paperIMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeactDNA-triggered escalation in early TNBC
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.